



BIS-DES-HYDROXY, BIS-DES-METHOXY CC-1065. SYNTHESIS, DNA BINDING, AND BIOLOGICAL ACTIVITY.

by M A Warpehoski and V S Bradford
Cancer and Viral Diseases Research
The Upjohn Company, Kalamazoo, MI 49001

Abstract The preparation of an optically pure bis-des-hydroxy, bis-des-methoxy analog (**3a**) of the antitumor antibiotic CC-1065 (**1**) is described. This compound displays a significantly lower induced circular dichroism in the presence of DNA than does **1**, indicating that the protected α -catechol substituents of **1** are important in stabilizing its non-covalent binding to DNA. Biological activities of **1** and **3a**, however, are similar, including the unusual phenomenon of delayed death in mice.

Studies on the non-covalent binding and covalent bonding of the potent antitumor antibiotic, CC-1065 (**1**), to DNA are unveiling a fascinating picture of molecular recognition with attendant implications for biological effects.¹ Our studies with analogs of **1** have identified structural features of this class of agents which are important for biological properties: 1) the chirality of the cyclopropyl ring, 2) the electrophilic reactivity of the left-hand segment, 3) the ring size of the central segment (presumably affecting conformational adaptability), and 4) the contour and length of the central and right-hand segments (determining hydrophobic and van der Waals interactions in the DNA minor groove).² One important compound developed in our analog program is shown by structure **2**. This compound matches the high potency of **1**, but shows greatly superior antitumor efficacy in animal models and, in contrast to **1**, does not cause delayed death in mice.³

To further explore the structural basis for the divergent biological properties of **1** and **2**, we targeted for synthesis the tetradesoxy analog **3a**. In view of the significant DNA binding (as reflected by DNA-induced circular dichroism) of simplified structures like **2**,² as well as modeling of the interaction **1** with DNA,^{1a-c} we surmised that close groove complementarity of the hydrophobic, concave surface of **1** was primarily responsible for its exceptional DNA binding parameters. We anticipated that **3a**, which shares this hydrophobic surface, should closely match **1** with respect to DNA binding. Recent crystallographic studies pointing to the importance of hydrophobic and van der Waals forces in the interaction of netropsin with the minor groove of DNA⁴ encouraged this view. According to this rationale the modified α -catechol substituents in the middle and right-hand segments of **1** appeared not to be critical in DNA binding. Furthermore, these substituents seemed likely culprits in the delayed toxicity of **1**, possibly via oxidative pathways.⁵






Scheme 1 illustrates several strategies for the synthesis of **3a**, based on the coupling of central and right-hand segment carboxylic acids to the nascent left-hand segment, the optically pure **7a** generated by deprotection of **7b**.⁶ A "sequential" strategy proved most successful. Thus, the 1,2-dihydro-3H-pyrrolo[3,2-e] indole **4**, prepared as previously described,^{7,8} was converted to **5b** with BOC-ON® in 95% yield. This was saponified to **6b** (89%). Similarly, **6a** was prepared by the reaction of **4** with potassium cyanate in acetic acid (52%), followed by saponification of **5a** (60% after chromatography).⁹ Freshly prepared **7a** (from HCl deprotection of 0.16 mmol of **7b**) was condensed with 1 eq of **6b** in the presence of 2 eq of 1-ethyl-3-(3-dimethylamino propyl)-carbodiimide hydrochloride (EDC) in DMA. This afforded **8** in 58% yield, after chromatography. Removal of the BOC group with anhydrous HCl in ethyl acetate, followed by EDC promoted condensation with **6a** in DMA gave, after chromatography, a mixture of **9a** and **3a**. Cyclization with triethylamine in aqueous acetonitrile afforded **3a** (60% from **8**).¹⁰

We also explored a convergent approach analogous to that used in the synthesis of **1**.⁶ Condensation of **4** with **6a**, followed by saponification, afforded **10a**⁹ (70% from **4**). Repeated attempts to condense this highly insoluble acid with **7a** in DMF or DMA, in the presence of EDC, failed to produce more than traces of **9a** or **3a**. To circumvent the extreme insolubility of **10a**, we prepared **10b** by the condensation of **4** with **6b**, followed by saponification. Although **10b** resisted purification attempts, it did condense with **7a** in DMA, in the presence of EDC. Extraction and chromatography afforded a mixture of **9b** and **3b**, which was converted to **3b** with triethylamine (17% yield from **7b**). Ring opening and removal of the BOC group with HCl, followed by reaction with potassium cyanate in acetic acid, gave an impure preparation of **9a**. Cyclization with triethylamine, followed by reverse phase chromatography, gave **3a** in about a 60% yield from **3b**, but the purity by this route remained unsatisfactory.

Table 1 compares some DNA binding and biological properties of **1**, **2**, **3a** and **3b**. Contrary to our expectations, **3a** showed only a slightly higher DNA induced circular dichroism (ICD) than did **2**, and far short of **1**. This result suggests that the oxygen substituents of the middle and right-hand portions of **1** are more important in promoting a tight binding complex with DNA than we had previously appreciated. The lower ICD of **3b** may reflect steric inhibition to binding in the DNA minor groove. The biological properties of **3a** and **3b**, on the other hand, resemble those of **1** much more than of **2**. Not only do the additional ethylene bridges on the central and right-hand indole units correlate with a loss of curative activity against P388 leukemia, but they also correlate with the unusual delayed death phenomenon shown by the natural product. Thus the *o*-catechol substituents of **1** are not required for the expression of this toxicity.

Scheme 1



I KOCN, HOAc, H₂O, reflux, 15 min, II BOC-ON^R, Et₃N, THF, 25 C, 24 h, III LiOH, pyridine, DMF, 60-70 C, then aq HCl, IV HCl, EtOAc, 25 C, 15-30 min, V EDC, DMF or DMA, 25 C, 24 hr, VI Et₃N, CH₃CN, H₂O, 25 C


Table 1 DNA Binding and Bioactivities

Compound	ICD ^a x10 ⁻³	ID ₅₀ ^b	P388 in vivo ^c		Delayed ^d Death
			%ILS	O D	
1	280	0.05	62	0.10	yes
2	120	0.004	(4)	0.025	no
3a	128	0.05	77	0.10	yes
3b	65	0.006	67	0.10	yes

a ICD = induced circular dichroism, expressed as molar ellipticity $11 \times 10^3 \text{ M}^{-1}$ calf-thymus DNA, $0.85 \times 10^{-5} \text{ M}$ drug, 0.01 M phosphate, pH 7.2, 25 °C, 24 hr, at long wavelength λ_{max} b ID₅₀ = nanomolar concentration of drug required to inhibit, by 50%, the growth of murine L1210 cells in a 3 day assay c Drug given intraperitoneally to mice implanted intraperitoneally with 10^6 P388 leukemia cells %ILS = percent increase in life span of treated mice over that of control tumored mice, at the optimal dose Parentheses indicate >30 day survivors, or cures, out of a group of 6 O D = optimal dose in mg/kg/injection on a days 1, 5, and 9 schedule d Therapeutic doses of drug administered intravenously to non-tumored mice, and followed for 90 days Most deaths occurred between 40 and 50 days following drug administration

References

- a) D R Needham - VanDevanter, L H Hurley, V L Reynolds, N Y Theriault, W C Krueger, and W Wierenga, *Nucleic Acids Res*, **12**, 6159 (1984) b) L H Hurley, V L Reynolds, D H Swenson, G L Petzold, and T A Scahill, *Science* **226**, 843 (1984) c) V L Reynolds, I J Molineux, D J Kaplan, D H Swenson, and L H Hurley, *Biochemistry* **24**, 6228 (1985) d) W C Krueger, L H Li, A Moscovitz, M D Prairie, G L Petzold, and D H Swenson, *Biopolymers* **24**, 1549 (1985) e) D R Needham-VanDevanter and L H Hurley, *Biochemistry* **25**, 8430 (1986) f) L H Hurley, D R Needham-VanDevanter, and C-S Lee, *Proc Natl Acad Sci USA*, in press (1987) Reviews g) V L Reynolds, J P McGovern, and L H Hurley *J Antibiotics* **39**, 319 (1986) h) L H Hurley, and D R Needham-VanDevanter, *Acc Chem Res* **19**, 230 (1986)
- a) M A Warpehoski, I Gebhard, R C Kelly, W C Krueger, L H Li, J P McGovern, M D Prairie, N Wicnienski, and W Wierenga, *J Med Chem*, submitted for publication b) W Wierenga, B K Bhuyan, R C Kelly, W C Krueger, L H Li, J P McGovern, D H Swenson, and M A Warpehoski, "Advances in Enzyme Regulation", G Weber, Ed., Pergamon Press, N Y, N Y, p 141 (1986)
- M A Warpehoski, *Tetrahedron Lett*, 4103 (1986)
- M L Kopka, C Yoon, D Goodsell, P Pjura, and R E Dickerson, *Proc Natl Acad Sci USA* **82**, 1376 (1985)
- D L Boger, R S Coleman, and B J Invergo, *J Org Chem*, **52**, 1521 (1987) These authors have expressed a similar assessment of structural features of 1
- R C Kelly, I Gebhard, N Wicnienski, P A Aristoff, P D Johnson, and D G Martin, *J Amer Chem Soc*, in press
- M A Warpehoski and V S Bradford, *Tetrahedron Lett*, 2735 (1986)
- All compounds reported were homogeneous by TLC unless otherwise stated and gave satisfactory IR, NMR, MS and exact mass and/or combustion analysis
- Compounds **6a**, **6b**, and **10a** gave identical spectra to those reported for these substances in Ref 5
- Spectral properties for compound **3a** IR (micro KBr) 3398, 1622, 1612, 1582, 1505, 1431, 1394, 1363, 1336, 1264 cm^{-1} , HRMS (FAB) m/e 612 2385 ($\text{C}_{35}\text{H}_{29}\text{N}_7\text{D}_4$ requires 612 2359), uv (MeOH) 318 nm ($\epsilon = 40,000$), 355 (34,000), CD (DMF) 370 (7000), 328 (0), 315 (-19500), 302 (0), 287 (35000), ^1H NMR (DMF- d_7 , 500 MHz COSY), δ 11.82 (s, 1H, NH), 11.52 (s, 2H, NH), 8.39 (bs, C4'-H), 8.14 (d, 1H, J = 9 Hz, C4"-H), 7.48 (d, 1H, J = 9Hz, C5'-H), 7.38 (d, 1H, J = 9Hz, C5"-H), 7.26 (s, 1H, C1'-H), 7.08 (s, 1H, C1"-H), 6.99 (s, 1H, C2-H), 6.79 (s, 1H, C5-H), 6.15 (s, 2H, CONH₂), 4.74 (t, 2H, C7'-H₂), 4.57 (m, 2H, C7-H₂) 4.15 (t, 2H, C7"-H₂), 3.53 (t, 2H, C8"-H₂), 3.40 (t, 2H, C8'-H₂), 3.24 (m, 1H, C8-H), 2.07 (s, 3H, Cl-CH₃), 2.04 (q, 1H, C9-H), 1.49 (t, 1H, C9-H) We thank Terry Scahill for assistance in running and interpreting this spectrum



(Received in USA 22 September 1987)